Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Fulcrum Therapeutics (FULC) over the last 7 years, with Dec 2024 value amounting to -$1.0 million.

  • Fulcrum Therapeutics' Change in Accured Expenses rose 14.30% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 468.67%. This contributed to the annual value of -$1.0 million for FY2024, which is 25.09% down from last year.
  • According to the latest figures from FY2024, Fulcrum Therapeutics' Change in Accured Expenses is -$1.0 million, which was down 25.09% from -$825,000 recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Change in Accured Expenses ranged from a high of $2.0 million in FY2020 and a low of -$1.0 million during FY2024.
  • In the last 3 years, Fulcrum Therapeutics' Change in Accured Expenses had a median value of -$825,000 in 2023 and averaged -$434,000.
  • Data for Fulcrum Therapeutics' Change in Accured Expenses shows a maximum YoY slumped of 248.65% (in 2023) over the last 5 years.
  • Fulcrum Therapeutics' Change in Accured Expenses (Yearly) stood at $2.0 million in 2020, then decreased by 1.32% to $1.9 million in 2021, then tumbled by 71.54% to $555,000 in 2022, then crashed by 248.65% to -$825,000 in 2023, then dropped by 25.09% to -$1.0 million in 2024.